DCI Cumberland in Clarksville, Tennessee - Dialysis Center

DCI Cumberland is a medicare approved dialysis facility center in Clarksville, Tennessee and it has 28 dialysis stations. It is located in Montgomery county at 312 Landrum Place, Clarksville, TN, 37043. You can reach out to the office of DCI Cumberland at (931) 645-1236. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. DCI Cumberland has the following ownership type - Non-Profit. It was first certified by medicare in August, 1981. The medicare id for this facility is 442518 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameDCI Cumberland
Location312 Landrum Place, Clarksville, Tennessee
No. of Dialysis Stations 28
Medicare ID442518
Managed ByDialysis Clinic, Inc.
Ownership TypeNon-Profit
Late Shifts No

Contact Information


312 Landrum Place, Clarksville, Tennessee, 37043
(931) 645-1236

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with DCI Cumberland from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1215966064
Doing Business AsDialysis Clinic Inc.
Address312 Landrum Pl Clarksville, Tennessee, 37043
Phone Number(615) 446-0111

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.70%67%
Patients who reported that nephrologists usually communicated and cared for them.17%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.13%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).48%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).39%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).13%14%

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.62%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.25%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.13%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).60%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).26%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).14%12%

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 82%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.18%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).67%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).19%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).14%12%

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data52
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL13

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center76
    Adult patient months included in Kt/V greater than or equal to 1.2641
    Percentage of adult patients getting regular hemodialysis at the center94
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

    Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

    Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

    In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

    World's most advanced real-time patient monitoring platform receives key US patent

    Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

    Congressional heavy-hitters back Michigan's MLR waiver request

    Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

    Read more Medical News

    › Verified 4 days ago

  • Peritoneal Dialysis
    Adult patients getting regular peritoneal dialysis at the center20
    Adult patient months included in Kt/V greater than or equal to 1.7187
    Percentage of adult patients getting regular peritoneal dialysis at the center88
    Percentage of pediatric patients getting regular peritoneal dialysis at the center

    News Archive

    Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

    Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

    Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

    In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

    World's most advanced real-time patient monitoring platform receives key US patent

    Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

    Congressional heavy-hitters back Michigan's MLR waiver request

    Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

    Read more Medical News

    › Verified 4 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DCI Cumberland with elevated calcium levels.

Patients with hypercalcemia94
Hypercalcemia patient months835
Hypercalcemia patients with serumcalcium greater than 10.2 mg1
Patients with Serumphosphor101
Patients with Serumphosphor less than 3.5 mg/dL11
Patients with Serumphosphor from 3.5 to 4.5 mg/dL23
Patients with Serumphosphor from 4.6 to 5.5 mg/dL24
Patients with Serumphosphor from 5.6 to 7 mg/dL26
Patients with Serumphosphor greater than 7 mg/dL16

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 68
Patient months included in arterial venous fistula and catheter summaries 514
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment57
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer12

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary86
Hospitalization Rate in facility183.1 (As Expected)
Hospitalization Rate: Upper Confidence Limit293.4
Hospitalization Rate: Lower Confidence Limit117.2

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at DCI Cumberland were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility23.2 (As Expected)
Readmission Rate: Upper Confidence Limit32.3
Readmission Rate: Lower Confidence Limit15.8

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at DCI Cumberland get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.21 (As Expected)
SIR: Upper Confidence Limit1.01
SIR: Lower Confidence Limit.01

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether DCI Cumberland's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 81
Transfusion Rate in facility43 (As Expected)
Transfusion Rate: Upper Confidence Limit87.1
Transfusion Rate: Lower Confidence Limit23.1

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at DCI Cumberland lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary373
Mortality Rate in facility19.3 (As Expected)
Mortality Rate: Upper Confidence Limit24.9
Mortality Rate: Lower Confidence Limit14.7

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago


Dialysis Facility in Clarksville, TN

DCI Cumberland
Location: 312 Landrum Place, Clarksville, Tennessee, 37043
Phone: (931) 645-1236
Clarksville Dialysis
Location: 231 Hillcrest Drive, Clarksville, Tennessee, 37043
Phone: (931) 645-9694
Clarksville North Dialysis
Location: 3071 Clay Lewis Road, Clarksville, Tennessee, 37040
Phone: (931) 552-0644
Ravalli Dialysis, Llc
Location: 1459 Fort Campbell Blvd, Clarksville, Tennessee, 37042
Phone: (931) 552-6491

News Archive

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

World's most advanced real-time patient monitoring platform receives key US patent

Isansys Lifecare, a digital healthcare company which has created and developed the world's most advanced real-time patient data collection and analysis platform, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor.

Congressional heavy-hitters back Michigan's MLR waiver request

Michigan Republican lawmakers Dave Camp and Fred Upton endorsed their home state's request for a temporary waiver from the health law's medical-loss ratio requirement. Meanwhile, The Miami Herald asks if ACOs will be the next health care revolution.

Read more Medical News

› Verified 4 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.